Qu Y. Cui
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study.
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study.
Journal: Blood cancer discovery
Published: April 10, 2026
Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up.
Journal: American journal of hematology
Published: September 17, 2025
Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma.
Journal: Frontiers in neurology
Published: February 03, 2025
High-dose methotrexate-based chemotherapy for induction remission of newly diagnosed primary CNS lymphoma: A systematic review and meta-analysis.
Journal: Medicine
Published: January 31, 2025
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Journal: The New England journal of medicine
Published: April 24, 2024
Efficacy and safety of chimeric antigen receptor T-cell therapy followed by allogeneic hematopoietic stem cell transplantation in 21 patients with Ph-like acute lymphoblastic leukemia
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 25, 2024
Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis.
Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
Published: September 19, 2023
Clinical observation of flumatinib combined with induction chemotherapy and sequential allogeneic hematopoietic stem cell transplantation in the treatment of 6 patients with newly diagnosed Ph(+) acute lymphocytic leukemia
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 22, 2023
Challenges in the management of primary central nervous system lymphoma.
Journal: Critical reviews in oncology/hematology
Published: September 08, 2022
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.
Journal: Cell research
Published: May 30, 2022
Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China.
Journal: Frontiers in oncology
Published: October 10, 2021
The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
Journal: BMC cancer
Published: August 08, 2021
Last Updated: 09/26/2026